Compare Medpace Holdings Inc (MEDP) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Microsoft — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Microsoft trades at $527.48 (market cap $3.88T). The key difference: Microsoft is far larger — about 230.7× Medpace Holdings Inc's market cap, and Microsoft pays a 0.75% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Microsoft for 142 Days on average.
| MEDP | MSFT | |
|---|---|---|
Market Cap | $16.82B | $3.88T |
Volume | 223,093 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $630.19 | $542.07 |
52-Week Low | $393.42 | $352.83 |
Typical Hold Time | 14 Days | 142 Days |
Enterprise Value | $16.44B | $3.86T |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Microsoft (MSFT) trades at $529.76, up 0.09% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 forecast. Revenue and net income have shown robust growth, reaching $281.72B and $101.83B in 2025, respectively. Analyst consensus is overwhelmingly positive, with 82% buy ratings and a $571.76 price target, indicating potential upside from current levels.
The outlook for MSFT remains favorable due to its leadership in AI and cloud computing, though risks include heightened capital expenditure concerns and competitive pressures. The stock's valuation multiples, such as a P/E of 29.51, reflect premium pricing but are supported by high profitability margins and growth prospects. Investors should weigh the strong institutional support against macroeconomic and sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
